Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients - Trial NCT06272227
Access comprehensive clinical trial information for NCT06272227 through Pure Global AI's free database. This Phase 4 trial is sponsored by Yonsei University and is currently Not yet recruiting. The study focuses on Sarcopenia. Target enrollment is 340 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yonsei University
Timeline & Enrollment
Phase 4
Feb 13, 2024
Sep 01, 2025
Primary Outcome
Improvement in SPPB score of 0.5 or more compared to the control group
Summary
This study aims to investigate the potential improvement in muscle function, compared to the
 placebo group, through the concurrent administration of denosumab and alfacalcidol over a
 one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65
 and older. The study is planned as a double-blinded randomized controlled trial, intending to
 recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5
 or more compared to the control group.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06272227
Non-Device Trial